Recolony AG

Colorectal cancer (CRC) is the third most prevalent cancer and the second leading cause of cancer mortality worldwide. In advanced stages, 5-year-survival rates are below 15%. Based on human CRC patient data, we identified specific bacteria that are less abundant in CRC patients compared to healthy individuals. When applied orally to mice carrying CRC tumors, we could induce a potent anti-tumor response and treat those tumors successfully. We aim to develop a live biotherapeutic product based on the lyophilized form of these bacterial strains in a gastro-resistant capsules. Now, we are addressing the regulatory requirements needed for preclinical/clinical development. In 2025, we plan to perform our first-in-human clinical trial in the USZ with CRC patients to test safety and tolerability.